Your browser doesn't support javascript.
loading
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model.
Koh, Jiae; Kim, Sohyun; Lee, Sang Nam; Kim, Sun-Young; Kim, Jung-Eun; Lee, Kyoung Young; Kim, Mi Soon; Heo, Jae Yeong; Park, Young Mee; Ku, Bo Mi; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Yang, Siyoung; Ha, Sang-Jun; Lim, Yong Taik; Ahn, Myung-Ju.
Afiliación
  • Koh J; Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Kim S; SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
  • Lee SN; SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
  • Kim SY; SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
  • Kim JE; SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
  • Lee KY; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Kim MS; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Heo JY; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Park YM; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Ku BM; Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Sun JM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Lee SH; Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Park K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea.
  • Yang S; Department of Pharmacology, Ajou University College of Medicine, Suwon, Republic of Korea.
  • Ha SJ; Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul, Republic of Korea.
  • Lim YT; SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Electronic address: yongtaik@skku.edu.
  • Ahn MJ; Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, Republic of Korea. Electronic address: silkahn@skku.edu.
Nanomedicine ; 37: 102415, 2021 10.
Article en En | MEDLINE | ID: mdl-34174421

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Receptor Toll-Like 7 / Receptor Toll-Like 8 / Receptor de Muerte Celular Programada 1 / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Receptor Toll-Like 7 / Receptor Toll-Like 8 / Receptor de Muerte Celular Programada 1 / Neoplasias Pulmonares Límite: Animals / Humans Idioma: En Revista: Nanomedicine Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article